๐ฌIn plain words
What the trial is, and whether it could suit you
The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.
Sign in to get the eligibility rules as simple questions to take to your doctor.
๐ Eligibility rules (as published)
SCREENING Inclusion Criteria:
* Age 30 years or older at the time of consent
* Either:
1. Self-identify as Black and/or African American OR
2. First-degree relatives (parents, siblings, or children) of patients of any race or ethnicity diagnosed with a plasma cell disorder, including MGUS, smoldering multiple myeloma (SMM), multiple myeloma (MM), solitary plasmacytoma, plasma cell leukemia, AL amyloidosis, POEMS syndrome, and Waldenstrรถm's Macroglobulinemia
* Capable and willing to provide informed consent. NOTE: HIPAA (Health Insurance Portability and Accountability Act) authorization for the release of personal health information may be included in the informed consent or obtained separately
* Reside in Charlotte, NC, or the surrounding area, based on self-report
SCREENING Exclusion Criteria:
* Self-reported history of MGUS, SMM, MM, AL amyloidosis, plasma cell leukemia, solitary plasmacytoma, Waldenstrom Macroglobulinemia, and POEMS.
LONGITUDINAL Inclusion Criteria:
* Test positive for monoclonal gammopathy during screening portion of the study
* Consent to the longitudinal portion of the study
LONGITUDINAL Exclusion Criteria:
* The participant previously underwent diagnostic work up as part of CHAAMP Internal Pilot that did not result in a diagnosis of MGUS, Smoldering Multiple Myeloma or other non-plasma cell disorder.